1. Home
  2. MLTX vs NEO Comparison

MLTX vs NEO Comparison

Compare MLTX & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoonLake Immunotherapeutics

MLTX

MoonLake Immunotherapeutics

N/A

Current Price

$18.91

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$7.44

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLTX
NEO
Founded
2021
2001
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
MLTX
NEO
Price
$18.91
$7.44
Analyst Decision
Buy
Buy
Analyst Count
12
7
Target Price
$27.50
$11.14
AVG Volume (30 Days)
828.6K
1.4M
Earning Date
05-11-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.63
Revenue Next Year
N/A
$9.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.95
$4.72
52 Week High
$62.75
$13.74

Technical Indicators

Market Signals
Indicator
MLTX
NEO
Relative Strength Index (RSI) 50.39 28.97
Support Level $16.52 $6.84
Resistance Level $19.03 $7.78
Average True Range (ATR) 0.89 0.39
MACD 0.04 0.02
Stochastic Oscillator 42.76 25.17

Price Performance

Historical Comparison
MLTX
NEO

About MLTX MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: